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doi:10.1016/j.jfma.2011.03.004Background/Purpose: The objective of this study was to describe factors associated with
bloodstream infections (BSIs) with non-albicans Candida species (NAC), compared with
Candida albicans BSIs, and antifungal susceptibility patterns in adult intensive care unit
(ICU) patients with chronic renal failure undergoing hemodialysis. To the best of our knowl-
edge, this is the first study to report the potential factors for NAC candidemia in ICU patients
with end-stage renal disease on chronic hemodialysis.
Methods: This prospective, observational, multicenter study was conducted in the two centers
of Baskent University between January 2007 and July 2010. All adult patients excluding
patients with neutropenia, malignancy, glucocorticoid treatment or AIDS, were included.
Results: Sixty cases (58.8%) of candidemia were due to C. albicans and 42 (41.2%) to NAC.
Multivariate regression analysis revealed that the presence of a central venous catheter was
the only risk factor independently associated with BSI due to NAC (pZ 0.046, odds ratio:
5.90, 95% confidence interval: 1.032e33.717). Mortality was more frequent in those with
NAC than C. albicans BSIs (64.3% vs. 55%), but the difference was not significant
(pZ 0.067). Except for two Candida glabrata strains, which were doseedependentlyversitesi Istanbul Saglik, Uygulama ve Arastirma Hastanesi, Altunizade M, Kisikli C. Oymaci S. No. 7,
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326 K. Serefhanoglu et al.fluconazole susceptible, all Candida species were susceptible to fluconazole, caspofungin, vor-
iconazole and amphotericin B.
Conclusion: Central venous catheterization was the only factor significantly associated with
BSI due to NAC in ICU patients with end-stage renal disease.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Chronic renal failure is a risk factor that is independently
associated with the development of nosocomial candide-
mia.1,2 Candidemia is a serious problem in intensive care
units (ICUs), and an estimated 33e55% of all episodes occur
in ICUs.3 Candida spp. are the third most common cause of
blood stream infections (BSIs) in ICUs, accounting for 10% of
such infections.4 Candidemia is associated with significant
mortality and prolonged hospital stay in ICU patients.5
C. albicans accounts for the majority of cases with
candidemia, but an increase in the proportion of the
bloodstream isolates due to non-albicans Candida spp.
(NAC) has been reported.1 NAC has even surpassed C.
albicans as a cause of candidemia in some European and
Latin American centers.6 Although C. albicans is generally
susceptible to fluconazole, several NACs have reduced
susceptibility to fluconazole and more likely require greater
doses of fluconazole or an another more effective agent
(e.g., amphotericin B) for clinical cure. Fluconazole is an
inexpensive and well-tolerated agent for the empirical
treatment of C. albicans candidemia. Therefore, data that
help differentiate C. albicans from NAC infections are of
value.4,7 However, factors associated with NAC infections
have differed in several surveys, and the reasons for this
changing epidemiology remain unclear.1,5 It may be partly
due to variations in several factors including the study
population and standard of the healthcare facilities avail-
able between institutions, localities and countries.8 In
addition to this changing epidemiology from several
surveys, information regarding the differences between C.
albicans and NAC BSIs in adult non-neutropenic ICU patients
remains uncommon.9 Therefore, there is an ever-increasing
need to determine the data regarding the factors associ-
ated with NAC BSIs in adult non-neutropenic ICU patients,
particularly in selected populations, and to the best of our
knowledge none in a single cohort of patients with end-
stage renal disease on chronic hemodialysis.
This is the first report to identify potential factors
associated with NAC BSIs that occurred in adult non-
neutropenic ICU patients with end-stage renal disease on
chronic hemodialysis at two tertiary care centers of
a Turkish university hospital. The second aim of this study
was to determine the susceptibility of the study isolates to
four antifungal agents.
Patients and methods
Surveillance
This prospective, observational, active surveillance of
candidemia was conducted at the two tertiary care centersof Baskent University (Istanbul and Ankara) from January
2007 to July 2010. All patients with end-stage renal disease
on chronic hemodialysis who were admitted to the adult
medical and surgical ICUs were evaluated for possible
inclusion in the study. Patients with Candida BSI were
eligible for inclusion if they had a length of stay > 48 hours
after ICU admission. Patients who developed a clinically
and microbiologically documented candidemia were iden-
tified through a microbiological laboratory survey. Episodes
of candidemia were defined as at least one positive blood
culture yielding Candida spp. in a patient with fever or
other clinical signs of infection. The cases were classified
according to the responsible Candida spp. in the C. albicans
and NAC candidemia groups. All patients with Candida BSI
were evaluated for inclusion in the study. After inclusion,
the patients were followed up for 30 days to assess the
outcome.
The potential factors have been evaluated by analyzing
the clinical history of the patients in the 4 weeks before
candidemia was diagnosed. A standardized case report
form was used to collect medical records to gather data
including: age; sex; underlying conditions (liver disease,
diabetes, pulmonary disease and cardiac disease); reason
for ICU admission (medical or surgical); total parenteral
nutrition (TPN) (> 2 days at time of diagnosis); surgical
procedures within 30 days; previous antibacterial or anti-
fungal therapies (> 2 days within previous 30 days); Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score; presence or absence of a central venous catheter
(CVC) (> 2 days at the time of diagnosis); time from
hospitalization to onset of candidemia (patient days); and
outcome. The outcome was defined as survival or death
within 30 days after the candidemia episode. Hospital
length of stay was calculated as the difference between the
date of admission (total of ICU and ward) and the date of
collection of a positive blood culture. When a patient had
more than one episode of candidemia, the first episode was
used in the potential factor analysis. All patients with
candidemia were initially treated with fluconazole. The
treatment was initiated empirically when candidemia was
clinically suspected. The therapy was modified to caspo-
fungin, or amphotericin B, when necessary, on the basis of
the Candida species or the clinical response. The initial
antifungal treatment was considered inadequate when> 72
hours elapsed between the time a culture was obtained and
initiation of the treatment to which the infecting organism
was shown to be susceptible. This was an observational
study, therefore, all decisions regarding patient manage-
ment, including the need to obtain blood cultures when
fever was present or sepsis was clinically suspected, and
the initiation of an antifungal agent and/or switching to
another antifungal agent were left to the discretion of the
attending physicians.
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hours if the blood culture system showed a positive sign
for Candida growth, and/or if there were pronounced
signs of local infection at the insertion site and/or clin-
ical suspicion of catheter-induced sepsis. Pediatric or
immunosuppressed patients including those with neu-
tropenia (neutrophil count  1000/mm3), glucocorticoid
and/or other immunosuppressive treatment, and malig-
nancy or AIDS were excluded from the study. Patients
with candidemia diagnosed before ICU admission were
also excluded.
Microbiological methods
The isolates of Candida spp. recovered from blood
cultures using the BACTEC 9050 system (Becton Dickinson,
Sparks, MD, USA) from each hospital were sent to the
Mycology Laboratory of Baskent University, Ankara, for
identification to the species level, and antifungal suscep-
tibility testing. Isolates were stored on YPD glycerol (1%
yeast extract, 2% peptone, 2% dextrose, and 3% glycerol)
at e70C until they were tested. The isolates were iden-
tified to the species level by API Candida (BioMerieux,
Marcy L-Etoile, France) in accordance with the manufac-
turer’s guidelines. Before testing, each isolate was sub-
cultured on a Sabouraud dextrose agar plate to check the
purity and optimal growth. Antifungal susceptibility
testing was performed using a broth microdilution assay
method described by the Clinical Laboratory Standards
Institute (CLSI).10 Candida parapsilosis ATCC 22019 and
Candida krusei ATCC 6258 were used as the quality control
strains. The following antifungal drugs, supplied by the
manufacturers as pure standard compounds, were tested:
amphotericin B (Sigma), fluconazole and voriconazole
(Pfizer, New York, NY, USA), and caspofungin (Janssen
Pharmaceutica, Titusville, NJ, USA). Interpretive suscep-
tibility criteria for fluconazole and voriconazole were
those recommended by the CLSI. For fluconazole, isolates
showing minimum inhibitory concentrations (MICs) 
8.0 mg/mL, 16e32 mg/mL and  64 mg/mL were regarded
as susceptible, dose-dependent susceptible (SDD) and
resistant, respectively. For voriconazole,  1.0 mg/mL,
2.0 mg/mL and  4 mg/mL were regarded as susceptible,
SDD and resistant, respectively. Due to the lack of defined
breakpoints for amphotericin B and caspofungin, MICs of 
2.0 mg/mL and  1.0 mg/mL were regarded as susceptible
for caspofungin and amphotericin B, respectively.11
Statistical analysis
The c2 test was used to compare categorical variables and
the t test to evaluate continuous variables. P values < 0.05
were considered significant. Multivariate, backwards
stepwise, logistic regression analyses were performed to
identify independent variables associated with candidemia
due to NAC. Potential risk factors were included in these
models if they were associated with the dependent vari-
ables in the univariate analyses at a statistical level of
p< 0.5. Mortality was evaluated using the KaplaneMeier
method and the log rank test. This study was approved byBaskent University Institutional Review Board and Ethics
Committee and supported by Baskent University Research
Fund.
Results
Three hundred and forty-six patients with candidemia
were identified during the study period. Of 191 (Istanbul
Center) and 612 (Ankara Center) patients with chronic
renal failure admitted in the study period, 114 had can-
didemia. Twelve patients were excluded from the study
because of lack of sufficient data (nZ 5), presence of
neutropenia (nZ 1), glucocorticoid and/or other immu-
nosuppressive treatment (nZ 2), a single positive blood
culture for Candida without signs of infection (nZ 2), and
presence of malignancy (nZ 2). Thus, a total of 102 cases
of candidemia were analyzed in Istanbul (nZ 24) and
Ankara (nZ 78) centers. Demographic and clinical infor-
mation about the patients with candidemia is summarized
in Table 1. All the variables were similar in the two
hospitals. In all patients, a single Candida spp. was iden-
tified. Sixty cases (58.8%) of candidemia were due to C.
albicans and 42 (41.2%) to NAC. Distribution of NAC is
shown in Table 2.
Table 3 compares the demographic and clinical char-
acteristics and outcomes of the patients in relation to the
causative species, C. albicans and NAC. Previous antibi-
otic therapy, total parenteral nutrition, the presence
of chronic renal failure, assisted ventilation, and CVC
were noted frequently in both groups. The results of the
univariate and multivariate analyses regarding compar-
ison of the distribution of different variables between the
two groups showed that the only factor independently
associated with candidemia due to NAC (in the multivar-
iate logistic regression analysis) was CVC placement
(pZ 0.046, odds ratio: 5.90, 95% confidence interval:
1.032e33.717). A total of 60 patients died within 30 days of
the diagnosis of candidemia, for an overall crude mortality
rate of 58.8%. The mortality was more frequent in patients
with NAC than those with C. albicans (64.3% vs. 55%,
respectively.), but the difference was not significant
(pZ 0.067).
The in vitro susceptibility results of the 102 Candida
isolates to four antifungal agents are shown in Table 4.
Except for two C. glabrata strains that were dose-
dependently fluconazole susceptible, all Candida species
were susceptible to fluconazole, caspofungin, voriconazole
and amphotericin B.
Discussion
Several published studies assessing factors associated with
candidemia due to NAC have generally focused on cancer
patients,4 mixed patient populations,12 or noncritically ill
patients.5 However, few data are available regarding the
differences in the factors associated with and outcome for
non-neutropenic ICU-acquired NAC BSIs.1,4,5 To the best of
our knowledge, this is the first study to report potential
factors associated with BSI due to NAC that occurred in ICUs
in a distinct patient population: patients with end-stage
Table 1 Demographic and clinical characteristics of candidemia cases in the Istanbul and Ankara centers, n (%).
Characteristics Patients (total, nZ 102) Patients (Istanbul)
(nZ 24)
Patients (Ankara)
(nZ 78)
P
Male sex 45 (44.1) 11 (45.8) 34 (43.6) 0,847
Age mean SD (range) 57.5 19.0 (18e90) 54.1 17.38 (27e85) 58.8 17.90 (18e88) 0.721
Hospital length of stay,
mean SD (range)a
34.98 17.46 (10e95) 36.29 22.19 (12e95) 34.54 16.49 (10e86) 0.891
30 days mortality 60 (58.8) 14 (58.3) 46 (59) 0.272
APACHE II score, mean SD (range) 24.8 5.02 (14e40) 24.9 6.60 (14e40) 24.4 4.22 (15e34) 0.320
Type of patient, medical/surgical 74/28 (72.5/27.5) 18/6 (75/25) 56/22 (71.8/28.2) 0.956
Species
Candida albicans/NAC 60/42 (58.8/41.2) 14/10 (58.3/41.7) 46/32 (59/41) 0.956
Inadequate initial antifungal
treatmentb
7 (6.9) 1 (4.2) 6 (7.7) 0.762
Primary site of infection 0.827
CVC 44 (43.1) 11 (45.8) 33 (42.3)
Unknown 58 (56.9) 13 (54.2) 45 (57.7)
Underlying diseases and conditions
Diabetes mellitus 50 (49) 12 (50) 38 (48.7) 0.913
Chronic obstructive lung Disease 3 (2.9) 1 (4.2) 2 (2.6) 0.684
Liver disease 2 (2) 0 2 (2.6) 0.428
Chronic heart failure 20 (19.6) 4 (16.7) 16 (20.5) 0.678
Therapeutic factors
Surgery within prior 4 wk 37 (36.3) 9 (37.5) 28 (35.9) 0.886
CVC in place at time of diagnosis 88 (86.3) 21 (87.5) 67 (85.9) 0.842
CVC days left in place prior to
development of candidemia,
mean (range)
25.40 15.09
(9e82)
26.85 14.75
(10e78)
24.22 13.61
(9e82)
0.628
Type of CVC 0.372
Temporary double-lumen catheter 78 (88.6) 20 (95.2) 58 (86.6)
Hemodialysis catheter 10 (11.4) 1 (4.8) 9 (13.4)
Total parenteral nutrition 83 (81.4) 19 (79.2) 64 (82.1) 0.751
Antibiotic therapy within prior 4 wk 101 (99) 23 (95.8) 78 (100) 0.08
Carbapenemc 60 (58.8) 14 (58.3) 46 (59) 0.956
Broad-spectrum Cephalosporind 47 (46.1) 10 (41.7) 37 (47.4) 0.620
Piperacillinetazobactam 39 (38.2) 9 (37.5) 30 (38.5) 0.932
Quinolonee 21 (20.6) 4 (16.7) 17 (21.8) 0.587
Aminoglycosidef 13 (12.7) 3 (12.5) 10 (12.8) 0.967
Glycopeptideg 72 (70.6) 16 (66.7) 56 (71.8) 0.630
Antifungal therapy within prior 4 wk 14 (13.7) 4 (16.7) 10 (12.8) 0.632
Fluconazole 13 (12.7) 4 (16.7) 9 (11.5)
Other 1 (1) 0 1 (1.3)
Assisted ventilation 53 (52) 13 (54.2) 40 (51.3) 0.636
Vascular access for hemodialysis 0.822
CVC 83 (81.4) 20 (83.3) 63 (80.8)
Fistula 15 (14.7) 3 (12.5) 12 (15.4)
Graft 4 (3.9) 1 (4.2) 3 (3.8)
APACHEZ acute physiology and chronic health evaluation; CVCZ central venous catheter; NACZ non-albicans Candida; SDZ standard
deviation.
a Number of days hospitalization before onset of candidemia.
b initial antifungal treatment was considered inadequate when > 72 hours elapsed between the time a culture was obtained and
initiation of treatment to which the infecting organism was susceptible.
c imipenem, meropenem.
d third- and fourth-generation cephalosporins including ceftriaxone, cefoperazoneesulbactam, ceftazidime and cefepime.
e ofloxacin, moxifloxacin, levofloxacin or ciprofloxacin.
f amikacin, gentamicin or netilmicin.
g vancomycin or teicoplanin.
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Table 2 Distribution of NAC isolated from blood, n (%).
Species Istanbul
(nZ 10)
Ankara
(nZ 32)
Total
(nZ 42)
Candida tropicalis 3 (30) 12 (37.5) 15 (35.7)
Candida glabrata 4 (40) 7 (21.9) 11 (26.2)
Candida parapsilosis 1 (10) 7 (21.9) 8 (19)
Othersa 2 (20) 6 (18.8) 8 (19)
NACZ non-albicans Candida.
a Candida famata (3), Candida humonicola (2), Candida keyfr
(2), Candida guillermondi (1).
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we conducted a prospective multicenter survey of candi-
demia, and excluded pediatric patients and patients with
malignancy, human immunodeficiency virus infection, or
neutropenia.
In the present study, C. albicans was found in 58.8%
of cases (Table 1). The predominance of C. albicans is
consistent with other reported ICU series.8,13e15 Despite
the fact that C. albicans remains the most common species
causing invasive candidiasis worldwide, a decreasing trend
in the isolation of C. albicans over time has been noted in
ICUs in several countries including the USA.16 Even in
a study reported by Bassetti et al,6 only 40% of candidemia
episodes in the ICU patients were caused by C. albicans. It
is noteworthy that, although hematologyeoncology
patients, in whom a high frequency of NACeassociated BSI
has been reported,5,12 were not included in our study (an
exclusion criterion), we found a relatively high proportion
of NAC (41.2%). One possible explanation for this could be
the patient cohort in our study. In a recent study, chronic
renal disease was found to be an independent risk factor
associated with candidemia caused by NAC.17 The
increased use of invasive medical procedures, particularly
CVCs (86.3%), which is well known to enhance the risk of
NAC (i.e., C. parapsilosis) infections,5 could have played
a role in promoting the increase in NAC BSIs in our
patients.
In our study, the results of the univariate and multi-
variate analyses regarding comparison of the distribution
of different variables between the two groups showed that
the only factor independently associated with candidemia
due to NAC (in the multivariate logistic regression analysis)
was CVC placement (pZ 0.046, odds ratio: 5.90, 95%
confidence interval: 1.032e33.717) (Table 3). This finding
is consistent with previously published independent
factors associated with ICU-acquired candidemia caused
by NAC.3e5 However, unlike other studies, we did not find
previous use of an antifungal agent (e.g., flucona-
zole),3,4,6,12 increasing age,12 or antibiotic exposure12 to
be independent factors associated with candidemia caused
by NAC. Pre-existing candiduria, which was not investi-
gated in the present study, is another factor previously
identified as being independently associated with candi-
demia caused by NAC.3e5 An important potential factor
difference between the present study and those discussed
above was the patient cohorts: the patients in the present
study did not have malignancy, human immunodeficiency
virus infection, or neutropenia, but they did have chronic
renal failure.It has been reported that Candida BSIs affect the
survival of ICU patients. Mortality in patients with ICU-
acquired candidemia has been reported to be 50e80%.18
In our study, the overall 30-day mortality rate in all
patients with candidemia was 58.8% (Table 1). Although the
mortality was more frequent in patients with NAC than with
C. albicans BSI, the difference was not statistically signifi-
cant (64.3% vs. 55%, pZ 0.067) (Table 3). Although the
presence of the increased mortality was reported in
patients with NAC candidemia,5,12,19,20 the relationship has
not been reported in other studies.4,9,18,21
Our results showed that fluconazole, caspofungin, vor-
iconazole and amphotericin B were very active against the
Candida bloodstream isolates tested (Table 4). Except for
two C. glabrata strains, which were fluconazole SDD, all
Candida species tested were susceptible to fluconazole,
caspofungin, voriconazole and amphotericin B. The
absence of fluconazole resistance among Candida strains in
our study may, in part, be explained by exclusion of the
immunosuppressed patients, who receive frequent fluco-
nazole prophylaxis and/or treatment in their clinical course
that is associated with azole resistance.22e24 In addition, in
those patients, the use of fluconazole has been implicated
in the increased isolation rate of C. glabrata and C. krusei
species, which are generally less sensitive or resistant to
azoles.24
The absence of fluconazole resistance among all Candida
strains tested has important implications for the manage-
ment of Candida infections, especially given that flucona-
zole is an efficacious, inexpensive and safe drug, and is one
of the most commonly used antifungal agents for the
treatment of candidemia.25 Our data pertaining to fluco-
nazole susceptibility for common Candida species (i.e. C.
albicans, C. parapsilosis and Candidia tropicalis) were
similar to that seen in other major surveillance studies of
Candida BSI isolates, in which resistance to fluconazole was
reported to be  3%.15,21 In contrast to our findings,
elevated rates of fluconazole resistance among C. glabrata
isolates have been reported in the USA (7e22.8%) and
Europe (4e40%).16,23 Our data pertaining to the excellent
activity of caspofungin, voriconazole and amphotericin B
against Candida species tested were in agreement with
other reports.16,22,26,27
Our data are consistent with the current belief that
antifungal susceptibility testing should not be routinely
performed for such common Candida species such as C.
albicans, C. parapsilosis and C. tropicalis, but may be
indicated for patients who fail to respond to initial therapy
or who develop breakthrough candidemia while receiving
fluconazole prophylaxis.28
In conclusion, among end-stage renal disease patients
with Candida BSIs in ICUs, although C. albicans remained
the leading Candida species, NAC was indentified in 41.2%
of the cases. Presence of CVCs was found to be the only
independent factor associated with BSIs due to NAC. The
severity of Candida BSIs was confirmed by an overall 30-day
mortality rate of 58.8%. The mortality was higher in
patients with BSIs due to NAC, however, the difference was
not significant. Our results also demonstrated that fluco-
nazole, voriconazole, caspofungin and amphotericin B were
active against almost all the Candida bloodstream isolates
tested.
Table 3 Risk factors for blood stream infection with non-albicans Candida in intensive care units patients with chronic renal
failure, n (%).
Univariate analyses Candida albicans
(nZ 60)
non-albicans
Candida (nZ 42)
Unadjusted
OR (95% CI)
P
Male sex 25 (41.7) 20 (47.6) 1.27 (0.57e2.81) 0.551
Age (y), mean SD (range) 58.1 19.79 (24e90) 56.8 18.03 (18e88) 1.07 (0.49e2.35) 0.868
Hospital length of staya,
mean SD (range)
35.9 18.93 (10e95) 33.6 15.22 (11e73) 0.96 (0.96e1.01) 0.381
Inadequate initial antifungal
treatmentb
4 (6.7) 3 (7.1) 0.88 (0.28e2.76) 0.925
Primary site of infection 0.69 (0.28e3.19) 0.275
CVC 25 (41.7) 19 (45.2)
Unknown 35 (58.3) 23 (54.8)
30 d mortality 33 (55) 27 (64.3) 0.067
APACHE II score, mean SD (range) 24.2 4.18 (16e34) 25.7 5.97 (14e40) 1.52 (0.69e3.37) 0.298
Type of patient, medical 35 (58.3) 24 (57.1) 1.14 (0.44e2.97) 0.783
Underlying diseases and conditions
Diabetes mellitus 30 (50) 20 (47.6) 0.86 (0.35e2.11) 0.745
Chronic obstructive lung disease 2 (3.3) 1 (2.4) 0.58 (0.05e7.04) 0.666
Liver disease 1 (1.7) 1 (2.4) 2.09 (0.07e60.92) 0.667
Chronic heart failure 10 (16.7) 10 (23.8) 1.33 (0.43e4.09) 0.615
Therapeutic factors
Surgery within prior 4 wk 21 (35) 16 (38.1) 0.87 (0.39e1.98) 0.749
CVC in place at time of diagnosis 48 (80) 40 (95.2) 5.30 (1.01e27.91) 0.028
CVC days left in place prior to
development of candidemia,
mean SD (range)
25.97 15.91 (9e82) 24.60 13.98 (10e73) 1.00 (0.97e1.03) 0.939
Type of CVC 0.82 (0.18e2.08) 0.73
Temporary double-lumencatheter 41 (85.4) 37 (88.1)
Hemodialysis catheter 7 (14.6) 3 (11.9)
Total parenteral nutrition 49 (81.7) 34 (81) 0.94 (0.31e2.81) 0.913
Assisted ventilation 30 (50) 23 (54.8) 1.00 (0.41e2.45) 0.998
Antifungal therapy within prior 4 wk 9 (15) 5 (11.9) 0.73 (0.21e2.60) 0.632
Fluconazole 8 (13.3) 5 (11.9)
Other 1 (1.7) 0
Antibiotic therapy within prior 4 wk 59 (98.3) 42 (100) 0.584 (0.496e0.689) 0.400
Broad-spectrum cephalosporinc 27 (45) 20 (47.6) 0.90 (0.41e1.98) 0.794
Carbapenemd 36 (60) 24 (57.1) 1.12 (0.51e2.50) 0.773
Piperacillinetazobactam 22 (36.7) 17 (40.5) 0.85 (0.38e1.91) 0.697
Quinolonee 11 (18.3) 10 (23.8) 0.72 (0.27e1.89) 0.501
Aminoglycosidef 8 (13.3) 5 (11.9) 1.14 (0.34e3.76) 0.831
Glycopeptideg 43 (71.7) 29 (69) 1.13 (0.48e2.68) 0.775
Vascular access for hemodialysis 1.24 (0.57e2.43) 0.917
CVC 48 (80) 35 (83.3)
Fistula 10 (18.3) 5 (11.9)
Graft 2 (1.7) 2 (4.8)
Multivariate regression analyses
CVC placement 5.90 (1.032e33.717) 0.046
APACHEZ acute physiology and chronic health evaluation; CIZ confidence interval; CVCZ central venous catheter; ORZ odds ratio;
SDZ standard deviation.
a Number of days of hospitalization before onset of candidemia.
b initial antifungal treatment was considered inadequate when > 72 hours elapsed between diagnosis of candidemia and initiation of
treatment to which the infecting organism was susceptible.
c third- and fourth-generation cephalosporins including ceftriaxone, cefoperazoneesulbactam, ceftazidime and cefepime.
d imipenem or meropenem.
e ofloxacin, moxifloxacin, levofloxacin or ciprofloxacin.
f amikacin, gentamicin or netilmicin.
g vancomycin or teicoplanin.
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Table 4 In vitro susceptibility of Candida bloodstream isolates to four antifungal agents.
Species (no. tested) Antifungal agent MIC (mg/mL) range No of isolates Ra (%) No of isolates SDD (%)
Candida albicans (60) Amphotericin B 0.03e1 0 (0) e
Caspofungin 0.015e0.03 0 (0) e
Voriconazole < 0.015e0.06 0 (0) 0 (0)
Fluconazole 0.01e2 0 (0) 0 (0)
Candida tropicalis (15) Amphotericin B 0.125e1 0 (0) e
Caspofungin 0.06e0.5 0 (0) e
Voriconazole 0.03e0.5 0 (0) 0 (0)
Fluconazole 0.250e4 0 (0) 0 (0)
Candida glabrata (11) Amphotericin B 0.06e1 0 (0) e
Caspofungin < 0.015e0.25 0 (0) e
Voriconazole 0.125e1 0 (0) 0 (0)
Fluconazole 1e16 0 (0) 2 (18.2)
Candida parapsilosis (8) Amphotericin B 0.125e1 0 (0) e
Caspofungin < 0.015e0.25 e
Voriconazole 0.03e0.25 0 (0) 0 (0)
Fluconazole 0.250e2 0 (0) 0 (0)
Other species (8)b Amphotericin B 0.125e2 0 (0) e
Caspofungin < 0.015e0.25 e
Voriconazole < 0.015e0.25 0 (0) 0 (0)
Fluconazole 0.125e2 0 (0) 0 (0)
All organisms (102) Amphotericin B 0.03e2 0 (0) e
Caspofungin < 0.015e0.5 0 (0) e
Voriconazole < 0.015e1 0 (0) 0 (0)
Fluconazole 0.01e16 0 (0) 2 (1.96)
RZ resistant; SZ sensitive; SDDZ susceptible, dose-dependent susceptible.
a Susceptibility breakpoints (mg/mL): fluconazole  8 (S),16e32 (SDD),  64 (R); amphotericin B  1.0 (S), > 1 (R); voriconazole  1.0
(S), 2.0 (SDD),  4 (R); caspofungin  2.0 (S), > 2 (R).
b Candida famata (3), Candida humonicola (2), Candida keyfr (2) and Candida guillermondi (1).
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